Business Overview: Vycor Medical, Inc. (OTC: VYCO)

Executive Summary

Vycor Medical is a tiny, 7-employee medical device company based in Boca Raton, Florida, running two business units — Vycor Medical (neurosurgery devices) and NovaVision (vision rehabilitation therapy) — that share resources to control costs. The company has carried a persistent working capital deficit and going-concern warnings for years, but has nonetheless maintained small, modestly growing revenue from a genuinely differentiated, FDA-cleared surgical access device.

1. Core Business Model & How They Work

[ Vycor Medical: ViewSite Brain Access System ] ➞ [ Hospitals/Surgeons/Distributors ]

[ NovaVision: VRT Software + NeuroEyeCoach ] ➞ [ Direct-to-Patient Setup + Monthly Therapy Fees ]

Both divisions share overhead and management resources, a cost-control structure appropriate for a company of this scale. NovaVision in particular is explicitly flagged by management as open to being partnered, licensed, or sold — reflecting its status as a secondary, non-core asset relative to the surgical device business.

2. Product Portfolio

3. Competitive Landscape

Item 1 names no direct competitors for the core VBAS product, noting only that NovaVision's former competitor, Sight Science, was acquired in 2012 (removing a direct rival from that market). This near-silence on competition is itself notable for a company this small — it suggests Vycor occupies a narrow enough niche that it does not face the kind of named, head-to-head competitors that larger device categories would.

4. Strategic Strengths & Risks

Strengths

• Regulatory credentials: ISO 13485:2016 and MDSAP certifications, FDA 510(k) clearance, CE Mark (Class III), and a Health Canada license — a full regulatory stack for a company this small.
• Growing core revenue: Vycor Medical division revenue grew to $1,796,070 in fiscal 2025.
• Shared-cost structure across both divisions keeps overhead low relative to the regulatory breadth the company maintains.
• Active corporate development: engaged Maxim Group LLC in August 2024 to pursue acquisitions and partnerships, and management is explicitly open to monetizing NovaVision.

Risks

• Going-concern warning from the auditor — the most serious possible financial red flag.
• Severe working capital deficit: about $4.2 million, including roughly $3.7 million owed to related parties — meaning the company is substantially financed by insiders rather than external capital.
• Minimal cash cushion: just $86,982 in cash at December 31, 2025, down from $105,648 a year earlier.
• Debt maturity risk: a $300,000 note to EuroAmerican Investment Corp. (plus accrued interest) matures June 30, 2026, with no assurance of further extension.
• Reliance on Fountainhead (the largest shareholder) for as-needed working capital — a single-point-of-failure funding dependency.
• No Item 1A risk factors disclosed (omitted as a smaller reporting company), limiting the depth of the company's own risk disclosure.

5. Financial Overview

6. Summary Conclusion

Vycor Medical is a genuinely tiny but real operating company: its ViewSite Brain Access System is FDA-cleared, CE-marked, and growing revenue in a niche narrow enough that the company names no direct competitors in its own filing. But the business is financially fragile — a going-concern warning, a $4.2 million working capital deficit dominated by related-party debt, and only $86,982 in cash mean Vycor's survival depends on continued support from its largest shareholder (Fountainhead) and successful refinancing of near-term debt, overshadowing whatever narrow product-level moat the VBAS device itself may hold.